Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2026

De novo and acquired MET amplification in patients with non-small cell lung cancer (NSCLC) treated with tepotinib: Results from a real-world data analysis in Australia (143781)

Surein Arulananda 1 , Ben Markman 2 , Timothy D Clay 3 , Sagun Parakh 4 , Ross Jennens 5 , Geoffrey Peters 6 , Stephanie Gasking 7 , Malinda Itchins 8
  1. Department of Medical Oncology, Monash Health, Melbourne, Australia
  2. Haematology and Oncology Centre, Cabrini Hospital and Monash University, Melbourne, Australia
  3. Medical Oncology Department, Saint John of God Subiaco Hospital, Perth, Australia
  4. Department of Medical Oncology, Austin Health, Melbourne, Australia
  5. The Department of Medical Oncology, Epworth Healthcare, Melbourne, Australia
  6. ANU Medical School, Australian National University, Canberra, Australia
  7. Merck Healthcare Pty. Ltd., Macquarie Park, Australia, an affiliate of Merck KGaA
  8. Department of Medical Oncology and School of Medicine, Royal North Shore Hospital and University of Sydney, Sydney, Australia

Aim

MET amplification (METamp) can develop as de novo or acquired resistance to tyrosine kinase inhibitor therapy in patients with NSCLC and actionable genomic alterations. Tepotinib, a highly selective oral MET kinase inhibitor, has shown promise in both settings. In Cohort B of VISION study (data cut off [DCO]: Aug 20, 2021), 24 patients with de novo METamp were treated with tepotinib; ORR was 41.7% (95% CI 22.1–63.4) and mPFS was 4.2 months (95% CI 1.4–15.6).  In INSIGHT 2 (DCO: Mar 28, 2023), 98 patients with EGFR-mutant lung cancer and acquired METamp (in tissue by FISH) were treated with osimertinib and tepotinib; ORR was 50.0% (95% CI 39.7–60.3) and mPFS was 5.6 months (95% CI 4.2–8.1). We present preliminary data from a real-world analysis of Australian patients with metastatic NSCLC and METamp in a cost-share program for tepotinib.

Methods

This was a retrospective analysis of adult patients with metastatic NSCLC with METamp detected by NGS or FISH, from the Australian tepotinib cost-share program between May 2023 and May 2025.

Results

As of May 2025, 16 patients were enrolled and received tepotinib. In the de novo group (N=6), median age was 62.5 years, 33.3% were female, and 50.0% had ECOG PS of 1. MET gene copy number (GCN) ranged from 3.9–20.0; ORR was 66.7%; median duration of treatment (mDoT) was 11 months; treatment was ongoing in 3 patients. In the acquired group (N=10), median age was 66.5 years, 50.0% were female, and 70.0% had ECOG PS of 1. MET GCN was 3.9–14; ORR was 70.0%; mDoT was 16 months; treatment was ongoing in 5 patients. No new safety signals were observed in either group.

Conclusions

Analysis of patients in Australian cost-share program showed that tepotinib is an effective and tolerable treatment in MET-amplified NSCLC.